Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein
- PMID: 31945421
- PMCID: PMC7114870
- DOI: 10.1016/j.virusres.2020.197863
Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein
Abstract
Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes severe pulmonary infection, with ∼35 % mortality. Spike glycoprotein (S) of MERS-CoV is a key target for vaccines and therapeutics because S mediates viral entry and membrane-fusion to host cells. Here, four different S subunit proteins, receptor-binding domain (RBD; 358-606 aa), S1 (1-751 aa), S2 (752-1296 aa), and SΔTM (1-1296 aa), were generated using the baculoviral system and immunized in mice to develop neutralizing antibodies. We developed 77 hybridomas and selected five neutralizing mAbs by immunization with SΔTM against MERS-CoV EMC/2012 strain S-pseudotyped lentivirus. However, all five monoclonal antibodies (mAb) did not neutralize the pseudotyped V534A mutation. Additionally, one mAb RBD-14F8 did not show neutralizing activity against pseudoviruses with amino acid substitution of L506 F or D509 G (England1 strain, EMC/2012 L506 F, and EMC/2012 D509 G), and RBD-43E4 mAb could not neutralize the pseudotyped I529 T mutation, while three other neutralizing mAbs showed broad neutralizing activity. This implies that the mutation in residue 506-509, 529, and 534 of S is critical to generate neutralization escape variants of MERS-CoV. Interestingly, all five neutralizing mAbs have binding affinity to RBD, although most mAbs generated by RBD did not have neutralizing activity. Additionally, chimeric antibodies of RBD-14F8 and RBD-43E4 with human Fc and light chain showed neutralizing effect against wild type MERS-CoV KOR/KNIH/002, similar to the original mouse mAbs. Thus, our mAbs can be utilized for the identification of specific mutations of MERS-CoV.
Keywords: Epitope; MERS-CoV; Monoclonal antibody; Neutralization; Neutralizing antibody; Pseudovirus.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare they have no potential conflicts of interest to disclose.
Figures
Similar articles
-
Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.J Virol. 2020 Nov 23;94(24):e01176-20. doi: 10.1128/JVI.01176-20. Print 2020 Nov 23. J Virol. 2020. PMID: 32967955 Free PMC article.
-
Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection.Viruses. 2018 Nov 30;10(12):680. doi: 10.3390/v10120680. Viruses. 2018. PMID: 30513619 Free PMC article. Review.
-
Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.J Virol. 2018 Apr 27;92(10):e02002-17. doi: 10.1128/JVI.02002-17. Print 2018 May 15. J Virol. 2018. PMID: 29514901 Free PMC article.
-
MERS-CoV spike protein: a key target for antivirals.Expert Opin Ther Targets. 2017 Feb;21(2):131-143. doi: 10.1080/14728222.2017.1271415. Epub 2016 Dec 21. Expert Opin Ther Targets. 2017. PMID: 27936982 Free PMC article. Review.
-
Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.J Virol. 2016 Dec 16;91(1):e01651-16. doi: 10.1128/JVI.01651-16. Print 2017 Jan 1. J Virol. 2016. PMID: 27795425 Free PMC article.
Cited by
-
ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks.Antib Ther. 2023 Dec 12;7(1):53-66. doi: 10.1093/abt/tbad030. eCollection 2024 Jan. Antib Ther. 2023. PMID: 38371953 Free PMC article.
-
Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus.Vaccine. 2023 May 16;41(21):3337-3346. doi: 10.1016/j.vaccine.2023.04.006. Epub 2023 Apr 10. Vaccine. 2023. PMID: 37085450 Free PMC article.
-
Application of Pseudotyped Viruses.Adv Exp Med Biol. 2023;1407:45-60. doi: 10.1007/978-981-99-0113-5_3. Adv Exp Med Biol. 2023. PMID: 36920691 Review.
-
Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the Coronaviridae and Togaviridae families (Review).Exp Ther Med. 2022 Nov 30;25(1):42. doi: 10.3892/etm.2022.11741. eCollection 2023 Jan. Exp Ther Med. 2022. PMID: 36569444 Free PMC article. Review.
-
Can anti-parasitic drugs help control COVID-19?Future Virol. 2022 Mar:10.2217/fvl-2021-0160. doi: 10.2217/fvl-2021-0160. Epub 2022 Mar 18. Future Virol. 2022. PMID: 35359702 Free PMC article. Review.
References
-
- Cho S.Y., Kang J.M., Ha Y.E., Park G.E., Lee J.Y., Ko J.H., Kim J.M., Kang C.I., Jo I.J., Ryu J.G., Choi J.R., Kim S., Huh H.J., Ki C.S., Kang E.S., Peck K.R., Dhong H.J., Song J.H., Chung D.R., Kim Y.J. MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study. Lancet. 2016;388(10048):994–1001. - PMC - PubMed
-
- de Groot R.J., Baker S.C., Baric R.S., Brown C.S., Drosten C., Enjuanes L., Fouchier R.A., Galiano M., Gorbalenya A.E., Memish Z.A., Perlman S., Poon L.L., Snijder E.J., Stephens G.M., Woo P.C., Zaki A.M., Zambon M., Ziebuhr J. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J. Virol. 2013;87(14):7790–7792. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources